At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET
Nkarta announced positive initial clinical data from its Ntrust program for NKX019 in myositis and systemic sclerosis, showing high response rates and a favorable safety profile with no CRS, ICANS, or GvHD. The company plans to discuss registrational pathways with the FDA and expects to report additional data in H1 2027.
- In myositis, 5/6 (83%) patients at 4 billion cells/dose achieved moderate or major TIS responses.
- In systemic sclerosis, 6/7 (86%) patients at 4 billion cells/dose achieved rCRISS-25 response or greater.
- No CRS, ICANS, IEC-HS, or GvHD observed across 40 patients in five indications.
- Median mRSS reduction of 15 points at Day 90 in systemic sclerosis; 71% of patients had ≥50% reduction.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access